SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract 2008

Rev Esp Quimioter 2008;21(2):93-98

Methicillin-resistant Staphylococcus aureus bacteremia. Predictor factors for an isolate with a vancomycin minimal inhibitory concentration ≥2 mg/l

 

M. Ortega ,  F. Marco ,  A. Soriano ,  M. Almela ,  J. A. Martínez ,  A. Muñoz ,  J. Mensa 

A greater rate of treatment failures with vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has been reported recently when the minimum inhibitory concentration (MIC) is ≥ 2 mg/l. This study has aimed to evaluate if there are clinical and/or epidemiological factors that predict isolation of a MRSA strain with MIC of vancomycin of ≥2 mg/L in the bacteremia episodes collected during a 15 year period (January 1991 to December 2005) in a tertiary urban hospital. During the study period, a total of 478 episodes of MRSA bacteremia were studied prospectively. The following clinical variables were recorded for each one: age, gender, comorbidity, previous administration of vancomycin or another antibiotic, prognosis of baseline diseases, bacteremia focus, shock, empiric antibiotic received and mortality. The MIC of vancomycin of 419 strains (88%) was determined with the E-test. In 216 (52%) of the isolations the MIC of vancomycin was 1.50 mg/L, in 110 (26%) of the cases it was ≤1 mg/l and in 93 (22%) 2 mg/l. Uni-and multivariate analyses were made, comparing the clinical variables of the patients infected by strains with MIC of vancomycin ≥2 mg/l regarding the MIC strains ≤1 mg/l. In the last 3 years of the study (2003-2005) the proportion of the strains with MIC of vancomycin ≥ 2 mg/l was significantly greater than those isolated with MIC ≤ 1 mg/L (44 % vs 3 %; p<0.001). In the multivariate analysis, the only clinical characteristic associated independently to the isolation of a strain with MIC ≥2 mg/l was the nosocomial-acquired infection OR (95 % CI):1.94 (1.04-3.63); p=0.04. Although the isolation of a MRSA strain with MIC of vancomycin ≥2 mg/l is more frequent in the nosocomial-acquired bacteremia episodes, in the clinical practice, it is not a useful predictive parameter because the frequency of isolation of these strains in the community is also high.    

 

Key words: Methicillin-resistant S. aureus bacteremia. Decrease sensitivity to vancomycin.Predictive factors. Empiric treatment of methicillin-resistant S. aureus bacteremia. 

Rev Esp Quimioter 2008;21(2):93-98 [pdf]

24 septiembre, 2009/por csanchez
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 csanchez https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png csanchez2009-09-24 10:28:312009-09-24 10:28:31Rev Esp Quimioter 2008;21(2):93-98

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2008;21(2):99-114 Link to: Rev Esp Quimioter 2008;21(2):99-114 Rev Esp Quimioter 2008;21(2):99-114 Link to: Rev Esp Quimioter 2008;21(2):99-114 Link to: Rev Esp Quimioter 2008;21(2):99-114 Rev Esp Quimioter 2008;21(2):99-114
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba

Utilizamos cookies propias y de terceros para garantizar el funcionamiento de la web, medir su uso y mejorar nuestros servicios. Puede aceptar todas las cookies, rechazar las no necesarias o configurar sus preferencias. Política de cookies

Configurar cookies

Necesarias para que la web funcione correctamente. No se pueden desactivar desde este panel.

Ayudan a medir el uso del sitio y mejorar sus contenidos.

Permiten publicidad, medición de campañas o personalización de anuncios.

Guardan preferencias o permiten contenido externo no necesario.